最新更新 :
19/11/2024
抗生素   Daptomycin  
注射液
溶液稳定性 混合物稳定性 影响稳定性的因素 兼容性 用药途径 引用文献 PDF
   化学式  

商品名   商品名     

商品名仅供参考, 药品所用的辅料可能依国家或厂商不同有所不同。

Cubicin 丹麦, 冰岛, 加拿大, 匈牙利, 卢森堡, 印度, 哥伦比亚, 土耳其, 墨西哥, 奥地利, 委内瑞拉, 希腊, 德国, 意大利, 挪威, 新西蘭, 日本, 智利, 法国, 波兰, 爱尔兰, 瑞典, 瑞士, 罗马尼亚, 美国, 芬兰, 英国, 荷兰, 葡萄牙, 西班牙, 阿根廷, 马来西亚
Daptomicina 西班牙
Daptomicine 英国
引用文献   注射液   引用文献 : Daptomycin  
种类 出版物
1937 文献 Lai JJ, Brodeur SK.
Physical and chemical stability of daptomycin with nine medications.
Ann Pharmacotherapy 2004 ; 38: 1612-1616.
2247 文献 Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 文献 Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2271 实验室 Daptomycine (Cubicin®) Résumé des caractéristiques du produits
Novartis 2006
3122 文献 Dotson B, Lynn S, Savakis K, Churchwell MD.
Physical compatibility of 4% sodium citrate with selected antimicrobial agents.
Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3218 文献 Peyro Saint Paul L, Albessard F, Gaillard C, Debruyn D, Ryckelynck J Ph, Antoine Coquerel, Lobbedez T
Daptomycin Compatibility in Peritoneal Dialysis Solutions
Perit Dial Int 2011 ; 31: 492?495.
3439 文献 Parra M.A, Campanero M.A, S?daba B, Irigoyen A, Garc?a-L?pez L,Fernandez-Reyes M.J, Ramon Azanza J.
Effect of Glucose Concentration on the Stability of Daptomycin in Peritoneal Solutions.
Perit Dial Int 2013 ; 33:458-461
3665 文献 Ortega R, Salmer?n-Garc?a A, Cabeza J, Capit?n-Vallvey L.F, Navas N.
Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer’s injection and stored in polypropylene syringes at 4 and -20°C.
Am J Health-Syst Pharm 2014 ; 71:956-959
3827 海报 Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 海报 Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 海报 So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3976 文献 Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055 文献 Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4074 文献 Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T.
Stability of daptomycin reconstituted vials and infusion solutions.
EJHP 2018 ; 25: 107-110.
4145 文献 Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254 文献 D'Huart E, Vigneron J, Demoré B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4380 实验室 Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4528 文献 Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4801 文献 Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales